Bladder cancer screening
- PMID: 8893869
Bladder cancer screening
Abstract
Transitional cell carcinoma of the bladder possesses several features that make it an ideal candidate for screening: metastases rarely occur before tumors invade the muscularis propria; superficial disease is treated very successfully by relatively inexpensive and nonmorbid means; this malignancy is almost never found incidentally at autopsy so that early detection cannot harm a patient; and almost all tumors cause hematuria if one tests frequently enough. When compared with a contemporary age, geography, and gender-matched unscreened population, bladder cancer screening in healthy men age 50 years and older by repeated home hematuria testing using chemical reagent strips significantly decreases bladder cancer morbidity and mortality and is cost-effective. A randomized prospective trial of bladder cancer screening in this population is recommended. Additionally, other potential means of bladder cancer screening and other target populations are discussed in this article.
Similar articles
-
Long-term outcome of hematuria home screening for bladder cancer in men.Cancer. 2006 Nov 1;107(9):2173-9. doi: 10.1002/cncr.22224. Cancer. 2006. PMID: 17029275
-
Early results of bladder-cancer screening in a high-risk population of heavy smokers.BJU Int. 2008 Aug;102(3):291-6. doi: 10.1111/j.1464-410X.2008.07596.x. Epub 2008 Mar 11. BJU Int. 2008. PMID: 18336612
-
NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.J Urol. 1999 Jan;161(1):62-5. J Urol. 1999. PMID: 10037369 Clinical Trial.
-
Markers of detection.Urol Oncol. 2007 Jul-Aug;25(4):344-7. doi: 10.1016/j.urolonc.2007.05.012. Urol Oncol. 2007. PMID: 17628306 Review.
-
Superficial bladder cancer: part 1. Update on etiology, classification and natural history.Expert Rev Anticancer Ther. 2006 Dec;6(12):1723-34. doi: 10.1586/14737140.6.12.1723. Expert Rev Anticancer Ther. 2006. PMID: 17181486 Review.
Cited by
-
Molecular Oncology of Bladder Cancer from Inception to Modern Perspective.Cancers (Basel). 2022 May 24;14(11):2578. doi: 10.3390/cancers14112578. Cancers (Basel). 2022. PMID: 35681556 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical